ES2578628T3 - Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4 - Google Patents

Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4 Download PDF

Info

Publication number
ES2578628T3
ES2578628T3 ES09818647.1T ES09818647T ES2578628T3 ES 2578628 T3 ES2578628 T3 ES 2578628T3 ES 09818647 T ES09818647 T ES 09818647T ES 2578628 T3 ES2578628 T3 ES 2578628T3
Authority
ES
Spain
Prior art keywords
heterocyclyl
alkyl
heteroaryl
represents hydrogen
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09818647.1T
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Abdul Rasheed Mohammed
Ishtiyaque Ahmad
Pradeep Jayarajan
Nagaraj Vishwottam Kandikere
Anil Karbhari Shinde
Rama Sastri Kambhampati
Gopinadh Bhyrapuneni
Jyothsna Ravula
Sriramachandra Murthy Patnala
Venkateswarlu Jasti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suven Life Sciences Ltd
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Application granted granted Critical
Publication of ES2578628T3 publication Critical patent/ES2578628T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula general (I) **Fórmula** en donde R1 representa hidrógeno, hidroxi, halógeno haloalquilo, haloalcoxi, nitro, amida, amina, ciano, carboxílico, cilcoalquilo, alquilo, alquenilo, alquinilo, alcoxi, arilo, aralquilo, heteroarilo, heteroaralquilo o heterociclilo; R2 representa hidrógeno, alquilo, cilcoalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo o heterociclilo; R3 representa**Fórmula** R4 representa hidrógeno, hidroxi, amina, alquilo, alcoxi, arilo, ariloxi, cilcoalquilo, cicloalcoxi, heteroarilo, heteroaralquilo o heterociclilo; R5 representa hidrógeno, alquilo, cicloalquilo o heterociclilo; R6 representa heteroarilo; R7 y R8 representan hidrógeno, alquilo, cicloalquilo o heterociclilo; opcionalmente R7 y R8 junto con el átomo de `N' pueden formar anillos de 4 a 9 miembros, que incluyen uno o más heteroátomos seleccionados de C, O, N, S.

Description

imagen1
imagen2

Claims (1)

  1. imagen1
    imagen2
ES09818647.1T 2009-09-14 2009-12-29 Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4 Active ES2578628T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2224CH2009 2009-09-14
INCH22242009 2009-09-14
PCT/IN2009/000745 WO2011030349A1 (en) 2009-09-14 2009-12-29 L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands

Publications (1)

Publication Number Publication Date
ES2578628T3 true ES2578628T3 (es) 2016-07-28

Family

ID=42126528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09818647.1T Active ES2578628T3 (es) 2009-09-14 2009-12-29 Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4

Country Status (17)

Country Link
US (1) US8598204B2 (es)
EP (1) EP2507225B1 (es)
JP (1) JP5540099B2 (es)
KR (1) KR101386354B1 (es)
CN (1) CN102639526B (es)
AU (1) AU2009352490B2 (es)
CA (1) CA2771885C (es)
DK (1) DK2507225T3 (es)
EA (1) EA020227B1 (es)
ES (1) ES2578628T3 (es)
HK (1) HK1173140A1 (es)
IL (1) IL218525A (es)
MX (1) MX2012002608A (es)
NZ (1) NZ598505A (es)
SG (1) SG178557A1 (es)
WO (1) WO2011030349A1 (es)
ZA (1) ZA201201429B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123115A1 (ja) * 2009-04-24 2010-10-28 日産化学工業株式会社 ビシクロカーバメート化合物からの2-アザアダマンタン化合物の製造方法
MX2011014019A (es) 2009-06-19 2012-02-22 Abbott Lab Derivados de diazahomoadamantano y sus metodos de uso.
CA2860192C (en) * 2011-12-22 2020-10-27 Connexios Life Sciences Pvt. Ltd. Derivatives of aza adamantane and uses thereof
RU2557249C1 (ru) * 2014-03-03 2015-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный технический университет" Способ получения 1-гидрокси-4-адамантанона
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
RU2020112854A (ru) 2017-11-30 2021-12-30 Арракис Терапьютикс, Инк. Фотозонды, связывающие нуклеиновые кислоты, и способы их применения
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
CN115677567A (zh) * 2022-11-15 2023-02-03 大唐环境产业集团股份有限公司 一种4-氨基-1-哌啶丙醇的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008965A1 (en) 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
US7405235B2 (en) * 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
US7419989B2 (en) 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
AP2007004067A0 (en) 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
CA2598516C (en) 2005-02-25 2010-05-11 Pfizer Inc. Benzisoxazole derivatives
EP1871772B1 (en) * 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
US8557994B2 (en) * 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives

Also Published As

Publication number Publication date
EA201270421A1 (ru) 2012-09-28
KR101386354B1 (ko) 2014-04-16
DK2507225T3 (en) 2016-07-04
CA2771885C (en) 2014-04-08
SG178557A1 (en) 2012-03-29
AU2009352490B2 (en) 2013-06-20
HK1173140A1 (en) 2013-05-10
IL218525A (en) 2014-12-31
EP2507225B1 (en) 2016-06-01
AU2009352490A1 (en) 2012-04-19
NZ598505A (en) 2013-01-25
JP2013504561A (ja) 2013-02-07
IL218525A0 (en) 2012-07-31
WO2011030349A1 (en) 2011-03-17
CA2771885A1 (en) 2011-03-17
MX2012002608A (es) 2012-04-02
ZA201201429B (en) 2012-10-31
CN102639526B (zh) 2014-06-04
CN102639526A (zh) 2012-08-15
JP5540099B2 (ja) 2014-07-02
EP2507225A1 (en) 2012-10-10
US20120277216A1 (en) 2012-11-01
KR20120081986A (ko) 2012-07-20
EA020227B1 (ru) 2014-09-30
US8598204B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
ES2578628T3 (es) Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4
ES2515194T3 (es) Derivados de pirrolidina
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
ES2590504T3 (es) N-ciclilamidas como nematicidas
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
CR20190244A (es) Agentes control de plaga
NZ732657A (en) Picolinamides with fungicidal activity and other related compounds
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
PE20130155A1 (es) Derivados de ariletinilo
PE20130187A1 (es) Bis(difluorometil) pirazoles como fungicidas
ECSP11011318A (es) Derivados de benzofurano
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
EA201170096A1 (ru) Замещенные производные пиримидона
JO2864B1 (en) Circular amine compounds
MY176278A (en) Process for producing diazabicyclooctane derivative and intermediate thereof
CR20150661A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
ES2586527T3 (es) Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
AR078606A1 (es) Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
ES2553030T3 (es) Compuestos plaguicidas